DE60226044D1 - Kristalline formen von fluvastatin-natrium - Google Patents

Kristalline formen von fluvastatin-natrium

Info

Publication number
DE60226044D1
DE60226044D1 DE60226044T DE60226044T DE60226044D1 DE 60226044 D1 DE60226044 D1 DE 60226044D1 DE 60226044 T DE60226044 T DE 60226044T DE 60226044 T DE60226044 T DE 60226044T DE 60226044 D1 DE60226044 D1 DE 60226044D1
Authority
DE
Germany
Prior art keywords
crystalline forms
fluvastatin
sodium
forms
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60226044T
Other languages
English (en)
Other versions
DE60226044T2 (de
Inventor
Der Schaaf Paul Adriaan Van
Claudia Marcolli
Martin Szelagiewicz
Andreas Burkhard
Heinz Wolleb
Annemarie Wolleb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Ciba SC Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Spezialitaetenchemie Holding AG, Ciba SC Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Application granted granted Critical
Publication of DE60226044D1 publication Critical patent/DE60226044D1/de
Publication of DE60226044T2 publication Critical patent/DE60226044T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
DE60226044T 2001-08-03 2002-07-25 Kristalline formen von fluvastatin-natrium Expired - Lifetime DE60226044T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01810756 2001-08-03
EP01810756 2001-08-03
PCT/EP2002/008276 WO2003013512A2 (en) 2001-08-03 2002-07-25 Crystalline forms of fluvastatin sodium

Publications (2)

Publication Number Publication Date
DE60226044D1 true DE60226044D1 (de) 2008-05-21
DE60226044T2 DE60226044T2 (de) 2009-05-14

Family

ID=8184071

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226044T Expired - Lifetime DE60226044T2 (de) 2001-08-03 2002-07-25 Kristalline formen von fluvastatin-natrium

Country Status (16)

Country Link
US (1) US6696479B2 (de)
EP (1) EP1429757B8 (de)
JP (2) JP4681808B2 (de)
KR (1) KR100975782B1 (de)
CN (2) CN102516150A (de)
AR (1) AR036205A1 (de)
AT (1) ATE391502T1 (de)
AU (1) AU2002333271B2 (de)
CA (1) CA2454072A1 (de)
DE (1) DE60226044T2 (de)
ES (1) ES2304140T3 (de)
HU (1) HUP0401141A3 (de)
IL (2) IL159861A0 (de)
PL (1) PL366905A1 (de)
RU (1) RU2334738C2 (de)
WO (1) WO2003013512A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
EP1525189A1 (de) * 2002-07-26 2005-04-27 Ciba Specialty Chemicals Holding Inc. Kristalline polymorphe und amorphe formen von benazepril-hydrochlorid
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
EP1726583A3 (de) * 2003-06-18 2007-05-09 Teva Pharmaceutical Industries Ltd Fluvastatin-natrium im Kristallform LXXIX, Verfahren zu dessen Herstellung, diesen enthaltende Zusammensetzungen und entsprechende Anwendungsverfahren
WO2005037424A1 (en) * 2003-10-06 2005-04-28 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
US7432380B2 (en) 2003-10-16 2008-10-07 Ciba Specialty Chemicals Corp. Crystalline form of Fluvastatin sodium
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
US20070173536A1 (en) * 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
US7795451B2 (en) * 2005-02-11 2010-09-14 Jubilant Organosys Limited Polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
WO2007039784A2 (en) * 2005-10-06 2007-04-12 Wockhardt Limited A novel crystalline polymorph of fluvastatin sodium and process for preparing it
US20090082572A1 (en) * 2005-11-14 2009-03-26 Hetero Drugs Limited Process for amorphous esomeprazole
JP2007246522A (ja) * 2006-02-27 2007-09-27 Teva Pharmaceutical Industries Ltd フルバスタチンナトリウムの新規形及びその調製方法
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
JP6115288B2 (ja) * 2012-04-27 2017-04-19 株式会社島津製作所 質量分析におけるピーク検出方法及びそのシステム
TW201806928A (zh) * 2016-07-01 2018-03-01 第一三共股份有限公司 胺基羧酸之酸加成鹽的結晶及其製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
AU570021B2 (en) * 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
PH23486A (en) * 1982-11-22 1989-08-16 Sanzoz Inc Indole analogs of mevalonolactone,pharmaceutical compositions containing the same and method of use thereof
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds
JP2004513112A (ja) * 2000-10-31 2004-04-30 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド フルバスタチンナトリウムの結晶形

Also Published As

Publication number Publication date
ATE391502T1 (de) 2008-04-15
US20030032666A1 (en) 2003-02-13
IL159861A0 (en) 2004-06-20
ES2304140T3 (es) 2008-09-16
RU2004106528A (ru) 2005-07-27
WO2003013512A2 (en) 2003-02-20
CN1536999B (zh) 2012-08-08
WO2003013512A3 (en) 2003-11-20
DE60226044T2 (de) 2009-05-14
EP1429757B8 (de) 2008-07-16
AU2002333271B2 (en) 2007-08-09
KR100975782B1 (ko) 2010-08-17
JP4681808B2 (ja) 2011-05-11
HUP0401141A2 (hu) 2004-09-28
CN102516150A (zh) 2012-06-27
IL159861A (en) 2009-02-11
US6696479B2 (en) 2004-02-24
EP1429757A2 (de) 2004-06-23
HUP0401141A3 (en) 2011-07-28
PL366905A1 (en) 2005-02-07
RU2334738C2 (ru) 2008-09-27
AR036205A1 (es) 2004-08-18
JP2005501838A (ja) 2005-01-20
EP1429757B1 (de) 2008-04-09
JP2010265308A (ja) 2010-11-25
CN1536999A (zh) 2004-10-13
KR20040022226A (ko) 2004-03-11
CA2454072A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
DE60226044D1 (de) Kristalline formen von fluvastatin-natrium
ATE420070T1 (de) Kristalline formen von atorvastatin
SE0201635D0 (sv) Novel compounds
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
DE60225040D1 (de) Montelukast-granulatformulierung
IS6451A (is) Nýjar 1,3-díhýdró-2H-indól-2-ón afleiður, framleiðsluaðferð og lyfjasamsetningar sem innihalda þær
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
EA200400491A1 (ru) Полиморфная форма римонабанта, способ её получения и содержащие её фармацевтические композиции
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
TW200420541A (en) Crystalline forms
SE9903291D0 (sv) New process
ME00455B (me) Novi postupak za industrijsku sintezu stroncijum ranelata i njegovih hidrata
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DE60112956T2 (de) Kristalline formen von fluvastatin sodium
WO2004050663A3 (en) An improved process for the preparation of cefuroxime sodium
RS8604A (en) Process for the production of beraprost and its salts
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
PT1102765E (pt) Processo para a sintese de derivados de (1h)-benzo¬c|quinolizin-3-onas
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
HUP0102243A2 (hu) sPLA2-inhibitor vegyületek betegség kezelésére
NO20033049L (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1-metylpiperidin
EA200300400A1 (ru) 17α-ФТОРАЛКИЛСТЕРОИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
ATE446952T1 (de) Herstellungsverfahren von 2-cyanopyridinen
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CIBA HOLDING INC., BASEL, CH

8328 Change in the person/name/address of the agent

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWAELTE

8364 No opposition during term of opposition